SuperworthCalidi Biotherapeutics shares outstanding CLDI
Diluted shares outstanding, averaged over each quarter, from 2021.
- Latest quarter, to Jun 30, 2026
- 1.4M
- On a year earlier
- +686.7%
- more shares
Calidi Biotherapeutics had 1.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 686.7% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 443.2K | +459% |
| FY2024 | 79.3K | +330% |
| FY2023 | 18.5K | +64% |
| FY2022 | 11.3K | −7% |
| FY2021 | 12.1K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 1.4M | +687% | |
| Q1 FY26 | 644.3K | +357% | |
| Q4 FY25 | 443.2K | +459% | |
| Q3 FY25 | 306.7K | +653% | |
| Q2 FY25 | 180K | +549% | |
| Q1 FY25 | 141.1K | +662% | |
| Q4 FY24 | 79.3K | +330% | |
| Q3 FY24 | 40.8K | +447% | |
| Q2 FY24 | 27.8K | +507% | |
| Q1 FY24 | 18.5K | +311% | |
| Q4 FY23 | 18.5K | +64% | |
| Q3 FY23 | 7.5K | +67% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Calidi Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.